CY1114514T1 - TRANS-4 - [[(5S) -5 - [[3,5-bis (trifluoromethyl) phenyl] methyl] (2-Methyl-2H-tetrazol-5-yl) amino] -2,3,4,5 -Tetrahydro-7,9-dimethyl-1H-1-benzazepine-1-yl] methyl] -cyclohexane-carboxylic acid - Google Patents

TRANS-4 - [[(5S) -5 - [[3,5-bis (trifluoromethyl) phenyl] methyl] (2-Methyl-2H-tetrazol-5-yl) amino] -2,3,4,5 -Tetrahydro-7,9-dimethyl-1H-1-benzazepine-1-yl] methyl] -cyclohexane-carboxylic acid

Info

Publication number
CY1114514T1
CY1114514T1 CY20131100930T CY131100930T CY1114514T1 CY 1114514 T1 CY1114514 T1 CY 1114514T1 CY 20131100930 T CY20131100930 T CY 20131100930T CY 131100930 T CY131100930 T CY 131100930T CY 1114514 T1 CY1114514 T1 CY 1114514T1
Authority
CY
Cyprus
Prior art keywords
methyl
tetrazol
tetrahydro
trifluoromethyl
trans
Prior art date
Application number
CY20131100930T
Other languages
Greek (el)
Inventor
Xinchao Chen
Scott Alan Frank
David Michael Remick
Steven Wayne Pedersen
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10728558.7A external-priority patent/EP2448933B1/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1114514T1 publication Critical patent/CY1114514T1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Αποκαλύπτονται ενώσεις του τύπου του τίτλου, trans-4-[[(5S)-5-[[[3,5-δις(τριφθορομεθυλ)φαινυλ]μεθυλ](2-μεθυλ-2Η-τετραζολ-5-υλ)αμινο]-2,3,4,5-τετραϋδρο-7,9-διμεθυλ-1Η-1-βενζαζεπιν-1-υλ]μεθυλ]-κυκλοεξανοκαρβοξυλικό οξύ, ως ελεύθερο οξύ ή φαρμακευτικώς αποδεκτό άλας αυτού, υδρίτης και υδρίτης σε κρυσταλλική μορφή, φαρμακευτικές συνταγοποιήσεις και μέθοδοι χρήσης.Trans-4 - [[(5S) -5 - [[[3,5-bis (trifluoromethyl) phenyl] methyl] (2-methyl-2H-tetrazol-5-yl) amino] - compounds of title are disclosed 2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl] methyl] -cyclohexanecarboxylic acid, as a free acid or a pharmaceutically acceptable salt thereof, hydrate and hydrate in crystalline form, pharmaceutical formulations and methods of use.

CY20131100930T 2009-06-30 2013-10-22 TRANS-4 - [[(5S) -5 - [[3,5-bis (trifluoromethyl) phenyl] methyl] (2-Methyl-2H-tetrazol-5-yl) amino] -2,3,4,5 -Tetrahydro-7,9-dimethyl-1H-1-benzazepine-1-yl] methyl] -cyclohexane-carboxylic acid CY1114514T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22170809A 2009-06-30 2009-06-30
EP10728558.7A EP2448933B1 (en) 2009-06-30 2010-06-28 Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid

Publications (1)

Publication Number Publication Date
CY1114514T1 true CY1114514T1 (en) 2016-10-05

Family

ID=58448779

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100930T CY1114514T1 (en) 2009-06-30 2013-10-22 TRANS-4 - [[(5S) -5 - [[3,5-bis (trifluoromethyl) phenyl] methyl] (2-Methyl-2H-tetrazol-5-yl) amino] -2,3,4,5 -Tetrahydro-7,9-dimethyl-1H-1-benzazepine-1-yl] methyl] -cyclohexane-carboxylic acid

Country Status (1)

Country Link
CY (1) CY1114514T1 (en)

Similar Documents

Publication Publication Date Title
TN2011000638A1 (en) Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
CY1126112T1 (en) PHARMACEUTICAL FORMS CONTAINING DAPAGLIFLOSIN HYDRATE PROPYLENE GLYCOL
CY1121631T1 (en) PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF
EA201001368A1 (en) HETEROCYCLIC UREA DERIVATIVES AND METHODS OF THEIR APPLICATION-211
NL300998I2 (en) Lusutrombopag or pharmaceutically acceptable salts or solvates thereof
BRPI0818193A2 (en) compound, pharmaceutically acceptable salt of a compound, pharmaceutical composition, and use of a compound
PE20170705A1 (en) NEW COMPOUNDS AS RET INHIBITORS (REORGANIZED DURING TRANSFECTION)
EP2133331A4 (en) 5-membered heterocyclic derivative and use thereof for medical purposes
EA201000702A1 (en) SOME DERIVATIVES 2-PYRAZINONE AND THEIR APPLICATION AS NEUTROFIL ELASTASIS INHIBITORS
MEP33308A (en) Benzimidazole derivative and use as angiotensin ii antagonist
UA107353C2 (en) Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof
EA201101301A1 (en) SODIUM SALT 5-CYCLOPROPYL-2 - {[2- (2,6-DIFTORPHENYL) PYRIMIDIN-5-IL] AMINO} BENZOIC ACID AS DHODH INHIBITORS
EA201001858A1 (en) HETEROCYCLIC DERIVATIVES OF UREA FOR THE TREATMENT OF BACTERIAL INFECTIONS
EA201001859A1 (en) HETEROCYCLIC DERIVATIVES OF UREA AND METHODS FOR THEIR APPLICATION
EP1830831A4 (en) Pharmaceutical formulations of gallium salts
EP2123641A4 (en) Crystal, amorphous form and salt of methyl n-ý3-(6,7-dimethoxy- 2-methylaminoquinazolin-4-yl)phenyl¨terephthalamic acid
DK1848419T3 (en) Diclofenac injection preparations and pharmaceutically acceptable salts thereof
CY1120728T1 (en) DIAZEPINONE DERIVATIVES USEFUL FOR THE TREATMENT OF FRAGILE X SYNDROME, PARKINSON'S DISEASE OR GASTRO-ESOPHAGEAL REFLECTION
CY1114514T1 (en) TRANS-4 - [[(5S) -5 - [[3,5-bis (trifluoromethyl) phenyl] methyl] (2-Methyl-2H-tetrazol-5-yl) amino] -2,3,4,5 -Tetrahydro-7,9-dimethyl-1H-1-benzazepine-1-yl] methyl] -cyclohexane-carboxylic acid
ZA201001817B (en) Crystalline hydrate of betamimetika and use as medicament thereof
AR083322A1 (en) COMPOUND (3 - {[{4- [4-AMINO-2- (ETOXIMETIL) -1H-IMIDAZOL [4,5-C] QUINOLIN-1-IL] BUTIL} (N, N-DIETILGLICIL) AMINO] METHYL} PHENYL ) METHYL ACETATE
ZA200706110B (en) Pharmaceutical formulations of gallium salts
TH115567B (en) Transnos-4 - (((5S) -5 - [[[3,5-bis (trifluoromethyl) phenyl] methyl] (2-methyl-2H-) Tetasol-5-il) amino) -2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzacipin-1-i L) - cyclohexane carboxylic acid
EP2119700A4 (en) Benzylamine derivative or pharmaceutically acceptable acid addition salt thereof, and use thereof for medical purposes
TH112269B (en) Methyl Pharmacy Acceptable Salt (3 - ([[3- (6-amino-2-butoxi-8-oxo-7,8-dihydro-9H-purin-9-il) propyl) (3-morpholin-4-ilpropyl) amino) - methyl)-phenyl) acetate And use in the treatment of disease